SCHEMBL6801538

SCHEMBL6801538

CN1CCN(c2cc3c(cc2F)c(=O)n(O)c(=O)n3-c2cccc(F)c2)CC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
LMNA P02545 2/20 0.46
ALDH1A1 P00352 5/20 0.41
DRD3 P35462 1/20 0.41
HTR3E A5X5Y0 1/20 0.40
HTR3B O95264 1/20 0.40
HTR3A P46098 1/20 0.40
HTR3D Q70Z44 1/20 0.40
HTR3C Q8WXA8 1/20 0.40
GAA P10253 2/20 0.39
POLB P06746 1/20 0.39
RAD52 P43351 1/20 0.39
KDM4E B2RXH2 4/20 0.38
NPC1 O15118 2/20 0.38
HPGD P15428 2/20 0.38
THRB P10828 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6799833 0.90 THRB (0.41) KMT2AMEN1LMNAALDH1A1GAA
SCHEMBL6798420 0.89 HTR7 (0.44) KMT2AMEN1LMNAALDH1A1DRD3
SCHEMBL6807011 0.88 LMNA (0.55) KMT2AMEN1LMNAALDH1A1DRD3
SCHEMBL6801016 0.85 KMT2A (0.44) KMT2AMEN1LMNAALDH1A1DRD3
SCHEMBL6800528 0.84 KMT2A (0.45) KMT2AMEN1LMNAALDH1A1DRD3
SCHEMBL6800837 0.82 TRPV4 (0.48) KMT2AMEN1LMNAALDH1A1DRD3
SCHEMBL6806917 0.82 PRKD3 (0.43) KMT2AALDH1A1POLB
SCHEMBL6806693 0.80 BRPF1 (0.43) LMNAALDH1A1GAANPC1THRB
SCHEMBL6801040 0.80 ALDH1A1 (0.40) KMT2AMEN1LMNAALDH1A1DRD3
SCHEMBL6802243 0.78 LMNA (0.43) KMT2AMEN1LMNAALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP claimed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US claimed
US-6825199-B2 7-Substituted quinazolin-2,4-diones useful as antibacterial agents WARNER-LAMBERT COMPANY 2004-11-30 US disclosed
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP disclosed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US disclosed
US-6331538-B1 TREATMENT OF BACTERIAL INFECTION WARNER-LAMBERT COMPANY 2001-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents NQO2, TOP1, TOP2A KMT2A 3798/4885MEN1 2437/4885LMNA 3642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.